A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
NCT06100003 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 104
Last updated 2024-02-07
Summary
The study is a real-world observational clinical study. Patients diagnosed as gastric cancer through histopathology were screened and enrolled. Before anti-tumor treatment, gastroscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. The investigators will perform a drug sensitivity testing based on a novel drug susceptibility testing method to test the commonly used anti-tumor treatment regimens. Patients were given conventional anti-tumor treatment according to the medical judgment of the doctors. Finally, the investigator will evaluate the consistency of clinical efficacy in gastric cancer treatment and drug susceptibility outcomes.
Conditions
- Gastric Cancer
- Organoids
Sponsors & Collaborators
-
Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences
collaborator UNKNOWN -
Precedo Pharmaceuticals Co. Ltd.
collaborator UNKNOWN -
Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China
collaborator UNKNOWN -
Funan Liu
lead OTHER
Principal Investigators
-
Zhenning Wang, doctor · The First Affiliated Hospital of China Medical Univeristy
-
Funan Liu, doctor · The First Affiliated Hospital of China Medical Univeristy
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-18
- Primary Completion
- 2025-10-31
- Completion
- 2025-12-01
Countries
- China
Study Locations
More Related Trials
-
Research on the Correlation Between Organoid Drug Sensitivity Testing and Precise Treatment of Gastrointestinal Tumors
NCT06332716 ·Status: RECRUITING ·Phase: PHASE3
-
Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
NCT06157216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients
NCT01100801 ·Status: UNKNOWN ·Phase: PHASE2
-
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study
NCT02555358 ·Status: COMPLETED ·Phase: PHASE2
-
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
NCT06196554 ·Status: RECRUITING
-
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
NCT06235164 ·Status: ACTIVE_NOT_RECRUITING
-
Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer
NCT00992199 ·Status: UNKNOWN ·Phase: PHASE2
-
A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
NCT01839500 ·Status: COMPLETED
-
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
NCT06134011 ·Status: ACTIVE_NOT_RECRUITING
-
Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
NCT06943794 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer
NCT05497739 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
NCT00983801 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Consistency of PDX Model for Predicting Therapeutic Effect of Gastric Cancer
NCT05616533 ·Status: RECRUITING
-
Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
NCT02736552 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
NCT04638959 ·Status: UNKNOWN
-
Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer
NCT01444521 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma
NCT00980382 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427 ·Status: COMPLETED
-
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
NCT04358341 ·Status: UNKNOWN ·Phase: PHASE2
-
Machine Learning-driven Noninvasive Screening of Transcriptomics Liquid Biopsies for Early Diagnosis of Occult Peritoneal Metastases in Locally Advanced Gastric Cancer
NCT06478394 ·Status: RECRUITING
-
Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers
NCT01650766 ·Status: UNKNOWN
-
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
NCT03957564 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
NCT02776878 ·Status: UNKNOWN ·Phase: NA
-
Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
NCT04826107 ·Status: UNKNOWN ·Phase: PHASE2
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING